Polymorphisms of survivin and its protein expression are associated with colorectal cancer susceptibility in Chinese population

DNA and Cell Biology

Volumn 32, Issue 5, 2013, Pages 236-242

  Li, Xia Bin ^a   Li, Shi Ning ^a   Yang, Zhi Hui ^a   Cao, Ling ^a   Duan, Fang Lei ^a   Sun, Xing Wang ^a  

^a SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PARAFFIN; SURVIVIN;

ADULT; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; CASE-CONTROL STUDIES; CHINA; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; POPULATION;

EID: 84877612445     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2012.1912     Document Type: Article

References (30)

1. Al Gizawy, S.M., Essa, H.H., Refaiy, A.M., et al. (2011). Prognostic value of expression of survivin And Ki-67 in head and neck squamous cell carcinoma treated by chemoradiotherapy. Life Sci J 8, 724-733.
2. Altieri, D.C. (2003). Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22, 8581-8589.
3. Altieri, D.C. (2003). Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3, 46-54.
4. Altieri, D.C. (2008). Survivin, cancer networks and pathwaydirected drug discovery. Nat Rev Cancer 8, 61-70.
5. Ambrosini, G., Adida, C., Sirugo, G., et al. (1998). Induction of apoptosis and inhibition of cell proliferation bysurvivin gene targeting. J Biol Chem 273, 11177-11182.
6. Antonacopoulou, A.G., Floratou, K., Bravou, V., et al. (2011). The survivin-31 SNP in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Cell Oncol (Dordr) 34, 381-391.
7. Aune, G., Stunes, A.K., Tingulstad, S., et al. (2011). The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas. Int J Clin Exp Pathol 4, 444-453.
8. Boman, B.M., Wicha, M.S., Fields, J.Z., and Runquist, O.A. (2007). Symmetric division of cancer stem cells a key mechanism in tumor growth that should be targeted in future therapeutic approaches. Clin Pharmacol Ther 81, 893-898.
9. Cheng, Z.J., Hu, L.H., Huang, S.J., et al. (2008). Correlation of-31G/C polymorphisms of survivin promoter to tumorigenesis of gastric carcinoma. Ai Zheng 27, 258-263.
10. Fortugno, P., Wall, N.R., Giodini, A., et al. (2002). Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 115, 575-585.
11. Gazouli, M., Tzanakis, N., Rallis, G., et al. (2009). Survivin-31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis 24, 145-150.
12. Gzy Zew Ska, J., Guzinska-Ustymow Icz, K., Lebelt, A., et al. (2004). Evaluation of proliferating markers K-i 67, PCNA in gastric cancers. Rocz Akad Med Bialymst 49, 64-66.
13. Han, C.H, Wei, Q., Lu, K.K., et al. (2009). Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer. Int J Clin Exp Med 2, 289-299.
14. Huang, J., Wang, J.-P., Wang, L., et al. (2009). Association between survivin promoter-31G/C polymorphism and genetic susceptibility to sporadic colorectal cancer. Chin J Pathophysiol 25, 2344-2348.
15. Jang, J.S., Kim, K.M., Kang, K.H., et al. (2008). Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 60, 31-39.
16. Li, D.X., Zeng, B., and Xie, L.Q. (2008). Expression and the clinical significance of survivin protein and b-catenin protein in primary hepatocellular carcinoma (HCC). J Mod Oncol 16, 62-66.
17. Li, F. (2005). Role of survivin and its splice variants in tumorigenesis. Br J Cancer 92, 212-216.
18. Li, F., and Brattain, M.G. (2006). Role of the survivin gene in pathophysiology. Am J Pathol 169, 1-11.
19. Li, F., Yang, J., Ramnath, N., et al. (2005). Nuclear or cytoplasmic expression of survivin:what is the significance? Int J Cancer 114, 509-512.
20. Mohamed, S., Yasufuku, K., Nakajima, T. (2009). Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications. Eur Respir J 33, 127-133.
21. Montorsi, M., Maggioni, M., Falleni, M., et al. (2007). Survivin gene expression in chronic liver disease and hepatocellular carcinoma. Hepatogastroenterology 54, 2040-2044.
22. Pennati, M., Folini, M., and Zaffaroni, N. (2008). Targeting survivin in cancer therapy. Expert Opin Ther Targets 12, 463-476.
23. Raff, M. (1998). Cell suicide for beginners. Nature 396, 119-122
24. Srivastava, K., Srivastava, A., and Mittal, B. (2012). Survivin promoter-31G/C polymorphism and cancer susceptibility: a meta-analysis. Mol Biol Rep 39, 1509-1516.
25. Taubert, H., Heidenreich, C., Holzhausen, H.J., et al. (2010). Expression of survivin detected by immunohistochemistry in the cytoplasm and in the nucleus is associated with prognosis of leiomyosarcoma and synovial sarcoma patients. BMC Cancer 24, 10, 65.
26. Thompson, C.B. (1995). Apoptosis is the pathogenesis and treatment of disease. Science 267, 1456-1462.
27. Weng, C.J., Hsieh, Y.H., Chen, M.K., et al. (2012). Survivin SNPcarcinogen interactions in oral cancer. J Dental Res 91, 358-363.
28. Xu, Y., Fang, F., Ludewig, G., et al. (2004). A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23, 527-537.
29. Yang, X., Xiong, G., Chen, X., et al. (2009). Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 135, 1341-1349.
30. Zhang, T., Fields, J.Z., Opdenaker, L., et al. (2010). Survivininduced aurora-B kinase activation: a mechanism by which APC mutations contribute to increased mitoses during colon cancer development. Am J Pathol 177, 2816-2826.